Imaging Matters: Decoding PSMA PET for Better Decision-Making

Release Date: September 12, 2025

Expiration Date: September 12, 2026

Activity Overview

Prostate cancer continues to pose substantial clinical challenges with increasing incidence and mortality rates in the United States. PSMA-directed radioligand therapy (RLT) and advanced imaging technologies have transformed the diagnosis and treatment of metastatic prostate cancer, but knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education. To address these unmet needs, PER® has developed this online activity that features expert video interviews.

Target Audience

This activity is directed toward medical oncologists, urologists, nuclear medicine physicians, radiologists, and radiation oncologists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

1. Determine the role of PSMA-based PET-CT scans as a key diagnostic and prognostic tool in prostate cancer
2. Discuss key elements and guidelines for PSMA PET-CT interpretation in clinical practice to support accurate clinical decision-making